Merck's CETP inhibitor trial, which lowered apoB and reduced coronary events, was not commercialized due to safety concerns and the availability of other treatments.

“Merck continued their trial so Lily what a potent Eva set your Pibb was seeing not only drastic raisings in HDL cholesterol but LDL cholesterol but you know pcsk9 inhibitors are starting to appear but in nobody's gonna ever prescribe this drug based on what it does to LDL cholesterol and we're not so convinced that raising HDL cholesterol matters anymore so they banned in the early this thing it was some futility so they bailed on their trial to people think they should have some people wish they would have continued that trial but Merck did continue and Merck did hit its end point that it did reduce coronary events it did drastically raise HDL cholesterol but it dramatically lowered a poby also so the dairy came to be what a see tip inhibitor does to the metric HDL cholesterol has nothing to do with anything but if it can lower April B it works but and may the trial was it worked but they're not gonna bring it to market because it in stays in a human body for years and I just for afraid of that they have no idea what might show up especially when there's no upside yeah we got other things that will give you that type of April be lowering that seemed to be safe and been around so Merck is not going to commercialize that product even though it has a successful trial”